LONDON BROKER RATINGS: BofA raises St James's Place and Quilter
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and on Monday: Read More
| Price | 13,880.00p on 27-01-2026 at 19:40:04 |
|---|---|
| Change | 128.00p 0.93% |
| Buy | 13,920.00p |
| Sell | 13,916.00p |
| Last Trade: | Unknown 412.00 at 14,259.804p |
| Day's Volume: | 1,444,248 |
| Last Close: | 13,880.00p |
| Open: | 13,800.00p |
| ISIN: | GB0009895292 |
| Day's Range | 13,736.00p - 13,986.00p |
| 52wk Range: | 9,574.00p - 14,408.00p |
| Market Capitalisation: | £215.18b |
| VWAP: | 13,867.70122p |
| Shares in Issue: | 1.55b |
Astrazeneca (AZN) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Unknown* | 412 | 14,259.804p | Currency Conversion OTC Trade |
17:06:25 - 27-Jan-26 |
| Sell* | 63 | 13,880.00p | SI Trade Suspected SELL Trade |
16:51:06 - 27-Jan-26 |
| Unknown* | 868 | 13,794.80512p | SI Trade Currency Conversion Negotiated Trade |
16:47:08 - 27-Jan-26 |
| Sell* | 2,728 | 13,855.227p | SI Trade Suspected SELL Trade |
16:47:06 - 27-Jan-26 |
| Sell* | 868 | 13,852.312p | SI Trade Suspected SELL Trade |
16:47:06 - 27-Jan-26 |
| Sell* | 29 | 13,880.00p | Automatic Execution |
16:37:27 - 27-Jan-26 |
| Sell* | 1,148 | 13,880.00p | Automatic Execution |
16:37:20 - 27-Jan-26 |
| Sell* | 8 | 13,880.00p | SI Trade |
16:35:09 - 27-Jan-26 |
| Sell* | 843 | 13,880.00p | SI Trade |
16:35:09 - 27-Jan-26 |
| Sell* | 50 | 13,880.00p | SI Trade |
16:35:09 - 27-Jan-26 |
Astrazeneca (AZN) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 20th Jan 2026 7:00 am | RNS | AstraZeneca to complete direct listing on NYSE |
| 8th Jan 2026 7:00 am | RNS | AZN new Head of Investor Relations Joris Silon |
| 2nd Jan 2026 3:00 pm | RNS | Total Voting Rights |
| 22nd Dec 2025 11:00 am | RNS | Director/PDMR Shareholding |
| 22nd Dec 2025 11:00 am | RNS | Director/PDMR Shareholding |
| 22nd Dec 2025 7:30 am | RNS | Enhertu granted BTD for post-neoadjuvant early BC |
| 22nd Dec 2025 7:30 am | RNS | Enhertu granted BTD for post-neoadjuvant early BC |
| 22nd Dec 2025 7:00 am | RNS | Update on LATIFY Phase III trial of ceralasertib |
| 22nd Dec 2025 7:00 am | RNS | Update on LATIFY Phase III trial of ceralasertib |
| 19th Dec 2025 11:00 am | RNS | Director/PDMR Shareholding |